CEO subs in

Houston startup spins off services to focus on esports and hires new CEO

Chris Buckner (left), who has served as FanReact's CEO since its founding in 2014, will be the CEO of Mainline, and Patrick Schneidau has been hired to serve as CEO of FanReact. Photos courtesy

Houston-based FanReact LLC has decided to divide and conquer. The sports marketing and digital solutions platform announced it will spin off its Mainline business as its own company so that it can better focus on the esports market.

Chris Buckner, who has served as FanReact's CEO since its founding in 2014, will be the CEO of Mainline, and Patrick Schneidau has been hired to serve as CEO of FanReact. Both companies are evaluating which assets and employees go where, but both entities plan to hire.

"We see a tremendous opportunity for Mainline in the esports market," says Buckner in a release. "The acceleration in growth in our media and collegiate partnerships gave us the opportunity to focus exclusively on that market. At this point it makes sense to separate our Mainline business from FanReact to give each organization dedicated resources to serve our customers and partners."

Schneidau has has a long career in Houston's tech scene. He spent 12 years at Houston software company PROS and was on the leadership team when the company went public in 2007. Since he left his position as CMO at PROS, he served as the chair of the Talent Committee for Houston Exponential and serves on the board for InnovationMap.

Together, Schneidau and Buckner see the potential for Houston to rise as an epicenter for esports.

"Houston has the second highest viewership of any city in the United States behind Los Angeles," Buckner tells InnovationMap. "I think that's a product of Houston's diversity."

The spinoff allows for Buckner to focus on Mainline, which has become necessary as the business grew over time.

"The Mainline business has been so successful in recent history, that it just made sense for us to dedicate resources toward building that market," Schneidau says. "The momentum in that market as a whole — and in Mainline specifically — is just too large to ignore and not put 100 percent of Chris' time in."

Houston makes sense for an esports market, and the city is on board. ESPN's inaugural collegiate esports championship will be hosted in Houston from May 10 to 12 at the George R Brown Convention Center during the Comicpalooza weekend — and local organizations are on board with the rise of esports in Houston.

"I have been personally in contact with every major university in the city and they all are taking esports seriously," Buckner says. It's actually a really exciting time for esports in Houston."

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News